Israeli pharmaceutical company PainReform has won approval to continue developing a pain relief drug that does not use potentially addictive opioids. The US Food and Drug Administration said the firm could carry out late-stage clinical studies for PRF-110, which prolongs the effectiveness of the post-operation painkiller ropivacaine. Earlier studies suggested it could relieve pain for up to 72 hours after surgery, 10 times longer than current medications. PainReform said the market for such treatment was worth $5bn. This is a crucial period when pain is maximal and opioids are often given, said Chief Executive Eli Hazum. A new study suggests that people who are overweight or obese may be at higher risk of heart disease compared with those who are not.
Israeli pharmaceutical company PainReform has won approval to continue developing a pain relief drug that does not use potentially addictive opioids. The US Food and Drug Administration said the firm could carry out late-stage clinical studies for PRF-110, which prolongs the effectiveness of the post-operation painkiller ropivacaine. Earlier studies suggested it could relieve pain for up to 72 hours after surgery, 10 times longer than current medications. PainReform said the market for such treatment was worth $5bn. A new study suggests that people who are overweight or obese may be at higher risk of heart disease compared with those who are not.